SirTlab Corporation Overview
SirTLab is the leader in Restoring SIRT6 Expression for Severe Liver Diseases and Diseases of Aging. Sirtuin 6 (SIRT6) is a Key Regulator for Health in all cells. Levels of SIRT6 are reduced in liver diseases: NASH1, other cirrhosis, metabolic syndrome, acetaminophen toxicity. SIRTLab patented SIRT6-mRNA-LNP2 for liver specific expression of SIRT6 is based on 18 years of research.
Cumulative Funding Raised Over Time ($)
$156KDec 2021
$641KMay 2025
Latest News
growth-positive
SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer
SIRTLab Corporation has appointed Michael G. Kauffman as Co-Chairman of the Board of Directors and Chief Medical Officer. Dr. Kauffman has a background in the biotechnology industry and has made major contributions to the approvals of three cancer drugs. SIRTLab focuses on the manipulation of sirtuin proteins for the treatment of severe liver diseases and longevity. Their lead program is centered around sirtuin 6 (SIRT6), which has shown promising results in restoring energy homeostasis, improving metabolic profiles, and prolonging lifespan in mice. The company aims to develop agents for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. The appointment of Dr. Kauffman is seen as a significant advancement for SIRTLab as they prepare to advance their novel class of agents.
Management Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.53M |
| Last funding | $485.76K |
| Stage | Seed |
| Rounds | 3 |
| Investors | 1 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.sirtlabcorp.com/ |
Locations
Ramat Gan, Israel
Photos & Videos
No files yet
SirTlab Corporation Business
Business models
B2B, B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsGenesTags (6)
anti-agingtherapeuticspharmaceuticalsgeneticspharma-companieschronic-patientsGeographic Markets
GlobalSirTlab Corporation Financials
$1.53M
Total funding
Undisclosed
Capital raised
$485.76K
Last funding
Seed
Funding stage
3
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$156KDec 2021
$641KMay 2025
Private Equity Funding
Equity crowdfunding
May 2025
$485.76K
PipelBiz
Undisclosed Round
Dec 2021
$155.56K
Non-Equity Funding
GrantEvent
Dec 2021
$888.89K
BIRD Foundation
SirTlab Corporation Lifecycle
Cumulative Funding Raised Over Time
$156KDec 2021
$641KMay 2025
All Events
Equity crowdfunding
May 2025
$485.76K
PipelBiz
Undisclosed Round
Dec 2021
$155.56K
GrantEvent
Dec 2021
$888.89K
BIRD Foundation
SirTlab Corporation News
1 article
growth-positive
SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer
SIRTLab Corporation has appointed Michael G. Kauffman as Co-Chairman of the Board of Directors and Chief Medical Officer. Dr. Kauffman has a background in the biotechnology industry and has made major contributions to the approvals of three cancer drugs. SIRTLab focuses on the manipulation of sirtuin proteins for the treatment of severe liver diseases and longevity. Their lead program is centered around sirtuin 6 (SIRT6), which has shown promising results in restoring energy homeostasis, improving metabolic profiles, and prolonging lifespan in mice. The company aims to develop agents for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. The appointment of Dr. Kauffman is seen as a significant advancement for SIRTLab as they prepare to advance their novel class of agents.
Management Changes
SirTlab Corporation Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
SirTlab Corporation Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Phone | +972773643522 |
| Creator | Adam Odesser |
| Creator email | adamodesser10@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-05-02T00:00:00.000Z |
| Created | 2018-04-29T00:00:00.000Z |